Immunological Markers for PML Prediction in MS Patients Treated With Natalizumab

Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2014.00668
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

High-Frequency MRI Monitoring Should Be Performed in Natalizumab-Treated MS Patients With Higher Risk of PML – Commentary

Multiple Sclerosis
Neurology
2017English

Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML

Neurology
Neurology
2011English

PML-IRIS During Fingolimod Diagnosed After Natalizumab Discontinuation

Case Reports in Neurological Medicine
2014English

Cerebellar Syndrome in a Man Treated With Natalizumab

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2019English

JC Virus Persistence Following Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients Treated With Natalizumab

Annals of Neurology
Neurology
2010English

Natalizumab for Relapsing-Remitting Ms in the Uk Top Cohort

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2014English

Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities

Multiple Sclerosis International
Neurology
2015English

Pregnancy Decision-Making in Women With Multiple Sclerosis Treated With Natalizumab

Neurology
Neurology
2020English

Folate Levels Measured by LC–MS/MS in Patients With Colorectal Cancer Treated With Different Leucovorin Dosages

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy